{"id":"https://openalex.org/W2994215274","doi":"https://doi.org/10.1182/blood.v112.11.1158.1158","title":"A Phase I/II Trial of Bortezomib, Tacrolimus and Methotrexate for Prophylaxis of Acute Graft Versus Host Disease after HLA Mismatched Reduced Intensity Transplantation.","display_name":"A Phase I/II Trial of Bortezomib, Tacrolimus and Methotrexate for Prophylaxis of Acute Graft Versus Host Disease after HLA Mismatched Reduced Intensity Transplantation.","publication_year":2008,"publication_date":"2008-11-16","ids":{"openalex":"https://openalex.org/W2994215274","doi":"https://doi.org/10.1182/blood.v112.11.1158.1158","mag":"2994215274"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v112.11.1158.1158","doi":"https://doi.org/10.1182/blood.v112.11.1158.1158","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.1158.1158","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029390145","display_name":"John Koreth","orcid":"https://orcid.org/0000-0002-7428-1330","observed_orcids":["https://orcid.org/0000-0002-7428-1330"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Koreth","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102723376","display_name":"Kristen E. Stevenson","orcid":"https://orcid.org/0000-0002-0647-1431","observed_orcids":["https://orcid.org/0000-0002-0647-1431"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristen Stevenson","raw_affiliation_strings":["Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045479163","display_name":"Haesook T. Kim","orcid":"https://orcid.org/0000-0003-4889-6849","observed_orcids":["https://orcid.org/0000-0003-4889-6849"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haesook T Kim","raw_affiliation_strings":["Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031812464","display_name":"Vincent T. Ho","orcid":"https://orcid.org/0000-0001-6839-3996","observed_orcids":["https://orcid.org/0000-0001-6839-3996"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vincent T Ho","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029278364","display_name":"Corey S. Cutler","orcid":"https://orcid.org/0000-0001-8728-4314","observed_orcids":["https://orcid.org/0000-0001-8728-4314"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corey S Cutler","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053410437","display_name":"Philippe A. Armand","orcid":"https://orcid.org/0000-0001-6098-1603","observed_orcids":["https://orcid.org/0000-0001-6098-1603"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philippe Armand","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068050082","display_name":"Robert J. Soiffer","orcid":"https://orcid.org/0000-0002-5810-1192","observed_orcids":["https://orcid.org/0000-0002-5810-1192"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert J Soiffer","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054037976","display_name":"Joseph H. Antin","orcid":"https://orcid.org/0000-0003-4627-1714","observed_orcids":["https://orcid.org/0000-0003-4627-1714"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph H Antin","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074589634","display_name":"Edwin Pascal Alyea","orcid":"https://orcid.org/0000-0002-1885-8430","observed_orcids":["https://orcid.org/0000-0002-1885-8430"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edwin P Alyea","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4264,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.70763081,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"112","issue":"11","first_page":"1158","last_page":"1158"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10373","display_name":"Renal Transplantation Outcomes and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2747","display_name":"Transplantation"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11189","display_name":"Transplantation: Methods and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.7400000095367432},{"id":"https://openalex.org/keywords/tacrolimus","display_name":"tacrolimus","score":0.9860000014305115},{"id":"https://openalex.org/keywords/low-dose-methotrexate","display_name":"low-dose methotrexate","score":0.8840000033378601},{"id":"https://openalex.org/keywords/hla-mismatched-transplantation","display_name":"HLA-mismatched transplantation","score":0.859000027179718},{"id":"https://openalex.org/keywords/reduced-intensity-conditioning","display_name":"reduced-intensity conditioning","score":0.9929999709129333},{"id":"https://openalex.org/keywords/peripheral-blood-stem-cell-transplantation","display_name":"peripheral blood stem cell transplantation","score":0.9670000076293945},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8619999885559082},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7929999828338623},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.7400000095367432},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.7110000252723694},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9369999766349792},{"id":"https://openalex.org/keywords/chronic-graft-versus-host-disease","display_name":"chronic graft-versus-host disease","score":0.7850000262260437},{"id":"https://openalex.org/keywords/busulfan","display_name":"busulfan","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8542141914367676},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.807145357131958},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.5920480489730835},{"id":"https://openalex.org/C2909675724","wikidata":"https://www.wikidata.org/wiki/Q411648","display_name":"Tacrolimus","level":3,"score":0.5590502619743347},{"id":"https://openalex.org/C2779972918","wikidata":"https://www.wikidata.org/wiki/Q1194520","display_name":"Graft-versus-host disease","level":3,"score":0.5185633301734924},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.4929196834564209},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4879016578197479},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4716807007789612},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.45071256160736084},{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.42168623208999634},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.41670069098472595},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3861633241176605},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.35298898816108704},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3215808868408203},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.18342342972755432},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.13160738348960876}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v112.11.1158.1158","doi":"https://doi.org/10.1182/blood.v112.11.1158.1158","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.1158.1158","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2080245154","https://openalex.org/W1977166918","https://openalex.org/W2518830792","https://openalex.org/W2976054443","https://openalex.org/W2979797496","https://openalex.org/W2782992298","https://openalex.org/W2144789671","https://openalex.org/W2032542882","https://openalex.org/W2980918225","https://openalex.org/W1991209725"],"abstract_inverted_index":{"Abstract":[0],"There":[1],"remains":[2],"a":[3,27,52,203,226,238,303,339,357,381,393,407],"need":[4],"for":[5,63,75,140,380,406],"better":[6],"control":[7,42],"of":[8,51,56,111,131,150,190,199,213,222,234,249,262,291,306,367,386,402,412,449],"acute":[9,96,112,361,450],"graft":[10,257],"versus":[11],"host":[12],"disease":[13],"(GVHD)":[14],"after":[15,43,66,87,438],"HLA":[16,67,454],"mismatched":[17,68,455],"peripheral":[18],"blood":[19],"stem":[20,104],"cell":[21,105],"(PBSC)":[22],"allogeneic":[23,44],"transplantation.":[24,45],"Bortezomib":[25,267],"is":[26,90,145,271,443,457,462],"small":[28],"molecule":[29],"proteasome":[30],"inhibitor":[31],"with":[32,77,117,206,356,388,431],"immunomodulatory":[33],"properties,":[34],"and":[35,59,101,113,135,166,275,341,378,415,424,434,459],"preclinical":[36],"data":[37],"indicate":[38],"utility":[39],"in":[40,246,259,321,335,353,365,400,452],"GVHD":[41,64,143,362,397,429,451],"We":[46],"report":[47],"on":[48,103,156,172,182,285,300],"Phase":[49,53,187,288],"I":[50,188],"I/II":[54,289],"trial":[55],"bortezomib,":[57,432],"tacrolimus":[58,161,433],"low":[60,167,435,447],"dose":[61,168,185,195,218,230,268,284,375,436],"methotrexate":[62,169,437],"prophylaxis":[65,144,430],"reduced":[69],"intensity":[70],"conditioning":[71,129],"(RIC)":[72],"PBSC":[73,88,441],"transplantation":[74,442],"patients":[76,179,201,224,236,278,299,337,355,370],"hematologic":[78],"malignancies.":[79],"Dose":[80],"limiting":[81],"toxicity":[82,98],"(DLT)":[83],"by":[84],"day":[85,383],"45":[86],"infusion":[89],"the":[91,183,191,247,254,260,273,286,292,297,342,453],"primary":[92],"endpoint,":[93],"evaluating":[94],"both":[95],"bortezomib":[97,146,184,194,217,229,374],"(e.g.":[99],"neuropathy)":[100],"impact":[102],"function.":[106],"Secondary":[107],"endpoints":[108],"include":[109],"incidence":[110,385,411],"chronic":[114],"GVHD.":[115],"Patients":[116],"1\u20132":[118],"locus":[119],"antigen/allele":[120],"mismatch":[121],"(HLA-A,":[122],"-B,":[123],"-C,":[124],"-DRB1)":[125],"are":[126,422],"eligible.":[127],"Pretransplant":[128],"consists":[130],"busulfex":[132],"(0.8":[133],"mg/kg/d)":[134],"fludarabine":[136],"(30":[137],"mg/m2/d)":[138],"each":[139,372],"4":[141],"days.":[142],"(dose":[147],"level":[148,196,219,231,269,376],"cohorts":[149],"1,":[151,197],"1.3":[152,270],"or":[153,316,390],"1.5":[154],"mg/m2":[155,171],"days":[157,173,334,352],"+1,":[158,174],"+4,":[159],"+7),":[160],"(days":[162],"\u22123":[163],"to":[164,211,244,327,345],"+180)":[165],"(5":[170],"+3,":[175],"+6,":[176],"+11).":[177],"13":[178,333],"were":[180],"enrolled":[181,281],"finding":[186],"portion":[189,290],"study.":[192],"At":[193,216,228],"one":[198],"5":[200,235],"had":[202,225,237,256],"possible":[204,239],"DLT,":[205],"poor":[207],"engraftment":[208,329,347],"likely":[209],"related":[210],"progression":[212],"underlying":[214],"MDS/AML.":[215],"1.3,":[220],"none":[221],"3":[223],"DLT.":[227,240],"1.5,":[232],"two":[233],"One":[241],"patient":[242],"failed":[243],"engraft":[245],"setting":[248,261],"minimally":[250],"treated":[251],"myeloproliferative":[252],"disease;":[253],"other":[255],"rejection":[258],"persistent":[263],"CLL":[264],"post":[265],"transplant.":[266],"considered":[272],"MTD,":[274],"6":[276,401],"additional":[277,460],"have":[279,302],"been":[280,312],"at":[282,373,419],"this":[283],"expanded":[287],"study":[293,301],"thus":[294],"far.":[295],"Overall,":[296],"19":[298,351],"median":[304,325,343],"follow-up":[305],"12":[307,403],"months.":[308],"No":[309,314],"neurotoxicity":[310],"has":[311,363,398],"noted.":[313],"platelet":[315,346],"neutrophil":[317,328],"nadir":[318],"was":[319,332,350],"noted":[320],"8":[322,354],"patients.":[323],"The":[324,446],"time":[326,344],"(ANC":[330],">500)":[331],"7":[336],"experiencing":[338],"nadir;":[340],"(Plts":[348],">20,000)":[349],"nadir.":[358],"Grade":[359],"2\u20134":[360],"occurred":[364,399],"2":[366],"17":[368],"evaluable":[369,404],"(one":[371],"1":[377,408,420],"1.5),":[379],"180":[382],"cumulative":[384,410],"14%,":[387],"relapse":[389,416],"death":[391],"as":[392],"competing":[394],"risk.":[395],"Chronic":[396],"patients,":[405],"year":[409,421],"50%.":[413],"Overall":[414],"free":[417],"survival":[418],"73%":[423],"58%":[425],"respectively.":[426],"In":[427],"summary,":[428],"busulfex/fludarabine":[439],"RIC":[440],"well":[444],"tolerated.":[445],"rate":[448],"context":[456],"encouraging,":[458],"accrual":[461],"ongoing.":[463]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2019-12-13T00:00:00"}